大B细胞淋巴瘤一线治疗试验的当前格局
至少25%至35%的大B细胞淋巴瘤(LBCL)患者一线治疗未获治愈,后续结局普遍较差。R-CHOP作为标准治疗已20年,仅近期pola-R-CHP挑战其地位。至少15项随机试验正在进行,在实验组方案、对照组选择、主要终点和患者选择策略上各不相同,部分针对特定生物学亚型或高危人群,另一些纳入老年或体弱患者,还有利用循环肿瘤DNA的反应适应策略。
要点
- 至少25%至35%的LBCL患者一线治疗未治愈,后续结局普遍较差。
- R-CHOP作为标准治疗已20年,仅pola-R-CHP近期挑战其地位。
- 至少15项一线随机试验进行中,设计差异大,部分针对特定亚型或高危人群。
核心结论
- 多种一线随机试验方法增加了总体成功可能性,但若多项试验成功,需在未以相同方式测试的多种潜在治疗选项中做选择,将带来挑战。
研究设计与样本
- 综述,总结主要正在进行的一线随机试验并讨论未来几年解读和应用其结果时将面临的问题。
主要发现
- 至少25%至35%的LBCL患者一线治疗未获治愈,后续结局普遍较差。
- R-CHOP作为标准治疗已20年,仅近期pola-R-CHP挑战其地位。
- 至少15项有前景的一线随机试验正在进行,在实验组治疗、对照组选择、主要终点和患者选择策略上不同。
- 部分试验针对特定生物学亚型,部分聚焦特定高危患者群体,另一些纳入老年或体弱患者。
- 利用循环肿瘤DNA的新型反应适应策略也在进行中。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
At least 25% to 35% of patients with large B-cell lymphoma (LBCL) are not cured with frontline treatment, with generally poor subsequent outcomes. This motivates ongoing and intense interest in improving the frontline treatment of this disease. R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) has remained the standard of care for 20 years despite dozens of trials aiming to improve upon this regimen, and only recently has a novel regimen (pola-R-CHP [polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone]) challenged its supremacy. Fortunately, at least 15 promising randomized trials evaluating new treatments in frontline LBCL treatment are underway. They differ not only in the therapy evaluated in the experimental arm, but in the choice of control arm, primary end point, and patient selection strategy, with some targeting specific biologic subtypes, some focusing on specific high-risk patient populations, and others enrolling older or frail patients. Novel response-adapted strategies leveraging circulating tumor DNA are also underway. Although this variety of approaches provides a welcome increase in the overall likelihood of success, it will also present challenges if several of these trials are successful and we must choose among multiple potential treatment options that were not all tested in the same fashion. In this review, we summarize the main ongoing frontline randomized trials and discuss some of the questions that we will face in interpreting and applying their results in clinical practice in the next few years.
引用
- Qualls D, Armand P, Salles G, et al. The current landscape of frontline large B-cell lymphoma trials. Blood. 2025. PMID: 39316716. doi:10.1182/blood.2023023789
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。